Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%

▤ Summary

Novo Nordisk ended its collaboration with Hims & Hers after accusing the telehealth company of promoting and selling compounded versions of Wegovy. The dispute centers on prescription drug compounding rules, patient safety claims, and alleged deceptive marketing. Hims & Hers said it will continue offering treatments and pushed back on Novo Nordisk’s assertions. The move also raises legal and regulatory risk for Hims & Hers while Novo Nordisk says it will keep working with telehealth partners that support branded treatment access.

▦ Linked Companies